We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


D3 Pharma and Encap Drug Delivery Continue Partnership

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "D3 Pharma and Encap Drug Delivery Continue Partnership"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

D3 Pharma Limited has announced its continuing partnership with Encap Drug Delivery to expedite the commercial manufacturing and product licensing programme for its proprietary high-dose oral vitamin D3 product, Plenachol™, for the treatment of vitamin D deficiency and insufficiency.

Plenachol™ is a patented liquid-filled capsule formulation of vitamin D3 which was developed in conjunction with Encap and is available at three dose-strengths: 20,000, 40,000 and 100,000 international units.

Plenachol™ has a unique formulation base which is free from animal derived excipients and peanut constituents.

The utility of Encap’s world-class capsule liquid-filling technology secures Plenachol™ as a first and best-in-class high-dose oral vitamin D 3 product.

Plenachol™ will continue to be made available as a Specials product during the pre-license phase via Encap Drug Delivery.

For more information regarding Plenachol™ Specials supply please contact: Dr Janice McLachlan (JMcLachlan@encapdrugdelivery.com).